Search

everythinglearnresearchcommunity

for

Search:↓

THH and PAD type III appear together early in hair growth, but deiminated THH appears later, suggesting another factor is involved.

A new peptide, FOL-005, may help treat excessive hair growth by reducing a hair growth promoter, FGF7.

Changing protein kinase levels in pituitary cells affects calcium flow and beta-endorphin release.

Replenishing iron after phlebotomy can cause relapse in porphyria cutanea tarda.

Targeting NMMHC IIA may help treat blood-brain barrier damage.

Cyproterone acetate effectively reduced hair growth in hirsute patients by lowering androgen levels and altering androgen metabolism.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

All-trans retinoic acid slows cell growth and increases cell death in goat hair follicles through a specific pathway.

PEVIII is a promising treatment for Pseudomonas aeruginosa keratitis.

Hormone-replacement therapy improved a woman's skin condition known as lymphomatoid papulosis.

TRPV3 and TRPV6 channels change structure to regulate calcium and heat responses.

The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.

Hinokitiol may help treat hair loss by reducing inflammation and promoting hair growth.

Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.

New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.

A small change in the TRPS1 gene leads to a less severe form of a syndrome affecting hair, nose, and finger development.

GnRH agonists can help manage recurrent priapism in sickle cell patients, but long-term safety is unclear.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.

A new mutation in the TRPS1 gene caused Trichorhinophalangeal syndrome in a 17-year-old, highlighting the need for genetic testing.

Platelet-rich plasma improves bladder function and reduces overactivity in ketamine-induced bladder issues.

Thiopurines help treat IBD but require genetic testing to avoid side effects.

Behavioral interventions, especially habit reversal training, are most effective for treating trichotillomania in children.

The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.

Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.

Botulinum neurotoxin A is effective and safe for treating various conditions, but more clinical trials are needed to fully assess its benefits and risks.

Thallium poisoning causes pain, hair loss, and nerve issues, treatable with hemoperfusion and hemodialysis.

Alpha-blockers and Finasteride effectively manage BPH symptoms long-term.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.